RPL17 and neoplasm: Combinations of PD1 antibodies with inhibition of the T cell exhaustion marker LAG-3 or an inhibition of the tryptophan catabolic enzyme IDO showed comparable results, i.e., increased efficacy of anti-PD1 treatment, later onset of neurological symptoms, and recomposition of the tumor associated microenvironment [31,32].